Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to $8.1 million.

  • Upstream Bio's Gains from Investment Securities rose 3043.91% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 3043.91%. This contributed to the annual value of $6.5 million for FY2024, which is 5579.46% up from last year.
  • As of Q3 2025, Upstream Bio's Gains from Investment Securities stood at $8.1 million, which was up 3043.91% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Upstream Bio's Gains from Investment Securities registered a high of $8.3 million during Q2 2025, and its lowest value of $3000.0 during Q4 2023.
  • For the 3-year period, Upstream Bio's Gains from Investment Securities averaged around $6.1 million, with its median value being $7.9 million (2025).
  • The largest annual percentage gain for Upstream Bio's Gains from Investment Securities in the last 5 years was 3043.91% (2025), contrasted with its biggest fall of 3043.91% (2025).
  • Upstream Bio's Gains from Investment Securities (Quarter) stood at $3000.0 in 2023, then soared by 207832.47% to $6.2 million in 2024, then skyrocketed by 30.44% to $8.1 million in 2025.
  • Its Gains from Investment Securities stands at $8.1 million for Q3 2025, versus $8.3 million for Q2 2025 and $7.9 million for Q1 2025.